Organisation: Novartis

Clearer guidance on parallel imports of medicinal products

The CJEU’s decision in this case - together with the other decisions issued on 17 November 2022 - provides important guidance for trademark owners and parallel importers in the pharmaceutical industry.

10 January 2023

Novartis succeeds via UKIPO’s critique of VESIQUE

This case shows that it is reasonable for a party to doubt the merits of a preliminary indication issued by the UKIPO when it is not in its favour.

04 January 2023

New CJEU decision on parallel importation of medicinal products: a victory for trademark owners

The decision confirms that repackaging may take place only where it is “objectively necessary” according to the BMS conditions.

06 December 2022